Table 2.
Characteristics of lung cancer in the study cohort and pre-operative findings.
| Variables | VATS (n = 55) | Open Surgery (n = 29) | p-Value |
|---|---|---|---|
| FEV1% (mean ± SD) | 80.0 ± 8.9 | 82.1 ± 16.4 | 0.447 |
| EF% (mean ± SD) | 57.7 ± 2.9 | 56.3 ± 3.0 | 0.041 |
| Cancer histology | 0.303 | ||
| NSCLC (n, %) | 47 (85.5%) | 27 (93.1%) | |
| SCLC (n, %) | 8 (14.5%) | 2 (6.9%) | |
| Localization | 0.916 | ||
| Left lung (n, %) | 24 (43.6%) | 13 (44.8%) | |
| Right lung (n, %) | 31 (56.4%) | 16 (55.2%) | |
| Lobe involved | 0.664 | ||
| Left upper lobe | 16 (29.1%) | 8 (27.6%) | |
| Left lower lobe | 8 (14.5%) | 5 (17.2%) | |
| Right upper lobe | 15 (27.3%) | 6 (20.8%) | |
| Right middle lobe | 4 (7.3%) | 5 (17.2%) | |
| Right lower lobe | 12 (21.8%) | 5 (17.2%) | |
| TNM classification | 0.233 | ||
| Stage I (all stages) | 14 (25.5%) | 4 (13.8%) | |
| Ia | 5 (9.1%) | 1 (3.4%) | |
| Ib | 9 (16.4%) | 3 (10.3%) | |
| Stage II (all stages) | 19 (34.5%) | 8 (27.6%) | |
| IIa | 11 (20.0%) | 3 (10.3%) | |
| IIb | 8 (14.5%) | 5 (17.2%) | |
| Stage III (all stages) | 22 (40.0%) | 17 (58.6%) | |
| IIIa | 14 (25.5%) | 10 (34.5%) | |
| IIIb | 8 (14.5%) | 7 (24.1%) | |
| Grading | 0.543 | ||
| I | 24 (43.6%) | 10 (34.5%) | |
| II | 18 (32.7%) | 13 (44.8%) | |
| III | 13 (23.6%) | 6 (20.7%) |
VATS—video-assisted thoracoscopic surgery; FEV—forced expiratory Volume; EF—ejection fraction (left ventricle); NSCLC—non-small cell lung cancer; SCLC—small cell lung cancer; TNM—tumor, node, metastasis; SD—standard deviation.